[I]MIBG is a better early marker of anthracycline cardiotoxicity than [F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.
Fiche publication
Date publication
septembre 2021
Journal
EJNMMI research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François, Dr COLLIN Bertrand, Pr COCHET Alexandre
Tous les auteurs :
Oudot A, Courteau A, Guillemin M, Vrigneaud JM, Walker PM, Brunotte F, Cochet A, Collin B
Lien Pubmed
Résumé
During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [F]FDG and [I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiotoxicity rat model.
Mots clés
Cardiotoxicity, Doxorubicin, Heart, [123I]MIBG, [18F]FDG
Référence
EJNMMI Res. 2021 Sep 20;11(1):92